Literature DB >> 24649130

Meaning of tumor protein 53-induced nuclear protein 1 in the molecular mechanism of gemcitabine sensitivity.

Naoki Nakaya1, Yasuhito Ishigaki2, Hideo Nakajima3, Manabu Murakami2, Takeo Shimasaki1, Takanobu Takata2, Mamoru Ozaki2, Nelson J Dusetti4, Juan L Iovanna4, Yoshiharu Motoo1.   

Abstract

Stress proteins of the pancreas, such as tumor protein 53-induced nuclear protein 1 (TP53INP1), are important factors in the invasion and metastasis of pancreatic cancer. TP53INP1 is a pro-apoptotic factor and is transcriptionally regulated in p53-dependent and -independent manners. A previous study proved that gemcitabine induces TP53INP1 expression in pancreatic cancer cells and the pancreatic cancer cell line (PANC-1). The present study aimed to clarify the association between TP53INP1 and gemcitabine sensitivity. The expression of TP53INP1 and its related factors, such as cell growth and cell cycle status in TP53INP1-knockout mouse embryonic fibroblasts [TP53INP1-/--mouse embryonic fibroblasts (MEFs)] to those in wild-type counterparts (TP53INP1+/+-MEFs) were compared. Flow cytometric analysis demonstrated no difference of the checkpoint function in TP53INP1-/--MEFs and TP53INP1+/+-MEFs when exposed to 10 ng/ml of gemcitabine. No significant difference was found in the level of p53 expression in the cell types, although the base level and gemcitabine-induced expression of p21 were significantly decreased in TP53INP1-/--MEFs, compared to those in wild-type counterparts. Results showed that gemcitabine induced the p21 expression in TP53INP1+/+-MEFs, although not in TP53INP1-/--MEFs. However, their respective cell-cycle checkpoints were not different. Therefore, TP53INP1 was found to be associated with drug sensitivity through control of the cell cycle.

Entities:  

Keywords:  cell cycle; gemcitabine; p21; p53; tumor protein 53-induced nuclear protein 1

Year:  2012        PMID: 24649130      PMCID: PMC3956314          DOI: 10.3892/mco.2012.8

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  23 in total

1.  Assignment of tumor protein p53 induced nuclear protein 1 (TP53INP1) gene to human chromosome band 8q22 by in situ hybridization.

Authors:  J Nowak; R Tomasini; M-G Mattei; L A Azizi Samir; J-C Dagorn; N Dusetti; J-L Iovanna; M-J Pébusque
Journal:  Cytogenet Genome Res       Date:  2002       Impact factor: 1.636

2.  Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.

Authors:  V Heinemann; Y Z Xu; S Chubb; A Sen; L W Hertel; G B Grindey; W Plunkett
Journal:  Mol Pharmacol       Date:  1990-10       Impact factor: 4.436

3.  Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage.

Authors:  Kiyotsugu Yoshida; Hanshao Liu; Yoshio Miki
Journal:  J Biol Chem       Date:  2005-12-23       Impact factor: 5.157

4.  Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1.

Authors:  Julien Gommeaux; Carla Cano; Stéphane Garcia; Meritxell Gironella; Sylvia Pietri; Marcel Culcasi; Marie-Josèphe Pébusque; Bernard Malissen; Nelson Dusetti; Juan Iovanna; Alice Carrier
Journal:  Mol Cell Biol       Date:  2007-01-22       Impact factor: 4.272

5.  Serum levels of pancreatitis-associated protein in digestive diseases with special reference to gastrointestinal cancers.

Authors:  Y Motoo; Y Satomura; I Mouri; H Mouri; K Ohtsubo; J Sakai; T Fujii; H Taga; Y Yamaguchi; H Watanabe; T Okai; N Sawabu
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

Review 6.  Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).

Authors:  Mariacristina Di Marco; Roberto Di Cicilia; Marina Macchini; Elisabetta Nobili; Silvia Vecchiarelli; Giovanni Brandi; Guido Biasco
Journal:  Oncol Rep       Date:  2010-05       Impact factor: 3.906

7.  Action of 2',2'-difluorodeoxycytidine on DNA synthesis.

Authors:  P Huang; S Chubb; L W Hertel; G B Grindey; W Plunkett
Journal:  Cancer Res       Date:  1991-11-15       Impact factor: 12.701

Review 8.  Genetics and biology of pancreatic ductal adenocarcinoma.

Authors:  Aram F Hezel; Alec C Kimmelman; Ben Z Stanger; Nabeel Bardeesy; Ronald A Depinho
Journal:  Genes Dev       Date:  2006-05-15       Impact factor: 11.361

9.  Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.

Authors:  Meritxell Gironella; Mylène Seux; Min-Jue Xie; Carla Cano; Richard Tomasini; Julien Gommeaux; Stephane Garcia; Jonathan Nowak; Man Lung Yeung; Kuan-Teh Jeang; Amandine Chaix; Ladan Fazli; Yoshiharu Motoo; Qing Wang; Palma Rocchi; Antonio Russo; Martin Gleave; Jean-Charles Dagorn; Juan L Iovanna; Alice Carrier; Marie-Josèphe Pébusque; Nelson J Dusetti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

10.  Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells.

Authors:  V Gandhi; S Mineishi; P Huang; Y Yang; S Chubb; A J Chapman; B J Nowak; L W Hertel; W Plunkett
Journal:  Semin Oncol       Date:  1995-08       Impact factor: 4.929

View more
  1 in total

1.  Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.

Authors:  Toshinori Ozaki; Mizuyo Nakamura; Takehiro Ogata; Meijie Sang; Hiroyuki Yoda; Kiriko Hiraoka; Meixiang Sang; Osamu Shimozato
Journal:  Oncotarget       Date:  2016-11-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.